SIRNAOMICS-B (02257) Grants Share Options and Restricted Share Units
SIRNAOMICS-B (02257) announced that on October 29, 2026, pursuant to the terms of the 2026 Share Option Scheme and the 2026 Restricted Share Unit Scheme, the Company granted approximately 893,600 share options to 25 option grantees and approximately 2,048,800 restricted share units to 27 restricted share unit grantees (excluding Dr. Pan Honghui), and conditionally granted 1,000,000 restricted share units to Dr. Pan Honghui, subject to acceptance by the option grantees, the restricted share unit grantees and Dr. Pan.
SIRNAOMICS-B (02257) announced that on October 29, 2026, pursuant to the terms of the 2026 Share Option Scheme and the 2026 Restricted Share Unit Scheme, the Company granted approximately 893,600 share options to 25 option grantees and approximately 2,048,800 restricted share units to 27 restricted share unit grantees (excluding Dr. Pan Honghui), and conditionally granted 1,000,000 restricted share units to Dr. Pan Honghui, subject to acceptance by the option grantees, the restricted share unit grantees and Dr. Pan.
Related Articles
Victory Giant Technology (02476) plans to make additional investments of no more than US$800 million and US$700 million in its wholly-owned indirect subsidiaries Victory Giant Technology (Thailand) and Victory Giant Technology (Vietnam), respectively.
MICROPORT (00853): Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. reported a net profit attributable to shareholders of RMB449 million for the first three quarters, up 4.55% year on year.
KEYMED BIO-B (02162) intends to purchase shares under the 2022 Restricted Share Unit Plan.
Victory Giant Technology (02476) plans to make additional investments of no more than US$800 million and US$700 million in its wholly-owned indirect subsidiaries Victory Giant Technology (Thailand) and Victory Giant Technology (Vietnam), respectively.
MICROPORT (00853): Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. reported a net profit attributable to shareholders of RMB449 million for the first three quarters, up 4.55% year on year.
KEYMED BIO-B (02162) intends to purchase shares under the 2022 Restricted Share Unit Plan.
